Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, a drug that acts like the blood sugar-controlling hormone amylin. Researchers are testing CagriSema as a treatment for ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

Novo said CagriSema appeared "to have a safe and well ... MariTide relies on another mechanism, mimicking GLP-1 and blocking GIPR. Over 52 weeks, patients taking MariTide lost about 20% of their ...